Andere Sprachen Evotec SE

Aktien

566480

DE0005664809

EVT

Biotechnologie

Realtime-Estimate Tradegate Andere Börsenplätze 15:38:02 14.01.2026			% 5 Tage	Veränd. 1. Jan.
6,342 ^EUR	-3,21 %		+1,91 %	+17,61 %

13.01.	Evotec: Michael Kaufman hält 5,03% der gesamten Stimmrechte und Instrumente an Evotec	RE
08.01.	Evotec erhält Gates-Stiftung-Zuschuss zur Nutzung von KI bei der Optimierung monoklonaler Antikörper	MT

Andere Sprachen

13.01.	Evotec says Michael Kaufman holds 5.03% of total voting rights and instruments in Evotec
12.01.	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
08.01.	Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies
08.01.	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
08.01.	Just – Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
06.01.	Evotec : Declaration of Compliance with the German Corporate Governance Code for the year 2025 (December 2025) 51.097 KB
06.01.	Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million
06.01.	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
06.01.	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
05.01.	Amgen Inc. acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company and Evotec SE in a transaction valued at $840 million.
02.01.	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
02.01.	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
02.01.	Evotec SE Announces Executive Changes
01.01.	Evotec : Current Company Presentation 999.321 KB (2026 01 EVT Company Presentation)
01.01.	Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
29.12.	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
22.12.	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
17.12.	Evotec SE Equity Buyback announced on August 6, 2024, has expired.
09.12.	Evotec SE: Prof. Dr. Iris Löw-Friedrich, buy
09.12.	L'Allemagne dope les actions de la défense, Air France coule après une opération de la CMA CGM
09.12.	Bourse : Renault va construire des Ford, Nvidia pourra vendre des H200 en Chine et Pepsi s'accord avec Elliott
09.12.	Evotec secondary ABB priced at EUR 5.10 per share, bookrunner says
09.12.	La Bourse en position latérale avant une baisse de taux à double tranchant
08.12.	Bookrunner says Evotec secondary ABB books are closed
08.12.	Sandoz finalise l'acquisition de Just-Evotec Biologics

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen MarketScreener Artikel MarketScreener Analysen Trading-Ideen

Andere Sprachen Evotec SE

Aktien

566480

DE0005664809

EVT

Biotechnologie

Andere Sprachen

Filter